Search - tctmd.com

Displaying 41 - 60 of 146

Sort: Relevancy | Date

Presentation NY Valves 2024

How to Define and Manage Subclinical Leaflet Thrombosis

Presenter: Hasan Jilaihawi

June 07, 2024

Presentation NY Valves 2024

Histopathology From Explanted Valves in Patients With HALT and RLM

Presenter: Stephanie Sellers

June 07, 2024

Presentation NY Valves 2024

Arial View of Antithrombotic Therapy Post TAVR

Presenter: Thomas Pilgrim

June 07, 2024

Presentation NY Valves 2024

What is the Optimal Post-LAAO Antithrombotic Regimen?

Presenter: Sameer Gafoor

June 07, 2024

Presentation NY Valves 2024

Valve Thrombosis and Antithrombotic Therapy After Surgical and Transcatheter Mitral Valve Replacement: A Systematic Review and Meta-Analysis

Presenter: Mark Zorman

June 06, 2024

Presentation EuroPCR 2024

Site-specific antithrombotic therapy: DESyne BDS Plus study 12-month outcomes

Presenter: Alexandre Abizaid

May 14, 2024

Presentation TCT 2023

Where Do Antithrombotics Fit In?

Presenter: Marc Bonaca

October 26, 2023

Presentation TCT 2023

Optimal Antithrombotic Strategies in MCS Use

Presenter: Mirvat Alasnag

October 26, 2023

Presentation TCT 2023

TCT 406: Effect of Antithrombotic Strategies on Total Outcome Events in Patients with Atrial Fibrillation after Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS

Presenter: Manasi Tannu

October 26, 2023

Presentation TCT 2023

Prophylactic Antithrombotic Therapy After TAVR

Presenter: Christian Hengstenberg

October 25, 2023

Presentation TCT 2023

Case Resolution: Long-term Therapy

Presenter: NULL

October 25, 2023

Presentation TCT 2023

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

Presenter: John Bittl

October 25, 2023

Presentation TCT 2023

Longer Term DAPT Is What The Guidelines and Data Support

Presenter: Mamas Mamas

October 25, 2023

Presentation TCT 2023

Case Continuation: In Hospital Management

Presenter: Davide Cao

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Presenter: Jennifer Rymer

October 25, 2023

$Unfractionated Heparin Still Works for Primary PCI!$

Presentation TCT 2023

Unfractionated Heparin Still Works for Primary PCI!

Presenter: Rod Stables

October 25, 2023

Presentation TCT 2023

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Presenter: Gregg Stone

October 25, 2023

Presentation TCT 2023

Case Presentation

Presenter: Davide Cao

October 25, 2023

Presentation TCT 2023

TCT 258: Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Patients After Transcatheter Aortic Valve Implantation

Presenter: Daniel Overduin

October 24, 2023

Advertisement

How to Define and Manage Subclinical Leaflet Thrombosis

Histopathology From Explanted Valves in Patients With HALT and RLM

Arial View of Antithrombotic Therapy Post TAVR

What is the Optimal Post-LAAO Antithrombotic Regimen?

Valve Thrombosis and Antithrombotic Therapy After Surgical and Transcatheter Mitral Valve Replacement: A Systematic Review and Meta-Analysis

Site-specific antithrombotic therapy: DESyne BDS Plus study 12-month outcomes

Where Do Antithrombotics Fit In?

Optimal Antithrombotic Strategies in MCS Use

TCT 406: Effect of Antithrombotic Strategies on Total Outcome Events in Patients with Atrial Fibrillation after Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS

Prophylactic Antithrombotic Therapy After TAVR

Case Resolution: Long-term Therapy

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

Longer Term DAPT Is What The Guidelines and Data Support

Case Continuation: In Hospital Management

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Unfractionated Heparin Still Works for Primary PCI!

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Case Presentation

TCT 258: Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Patients After Transcatheter Aortic Valve Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content